Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group

Cytori Therapeutics (NASDAQ:CYTX) has been given a $4.00 price objective by investment analysts at Maxim Group in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Finally, ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

Cytori Therapeutics (NASDAQ:CYTX) remained flat at $$0.31 on Tuesday. The company had a trading volume of 557,000 shares, compared to its average volume of 2,378,091. The stock has a market cap of $11.06, a price-to-earnings ratio of -0.34 and a beta of 3.11. Cytori Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $2.13.

In other Cytori Therapeutics news, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ag Postfinance sold 236,155 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $0.34, for a total transaction of $80,292.70. Following the completion of the sale, the insider now directly owns 5,311,451 shares of the company’s stock, valued at approximately $1,805,893.34. The disclosure for this sale can be found here. Insiders sold 408,785 shares of company stock valued at $142,987 in the last ninety days. 1.90% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the business. Sabby Management LLC boosted its stake in shares of Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Cytori Therapeutics by 81.9% during the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares during the last quarter. 10.82% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/13/cytori-therapeutics-cytx-given-a-4-00-price-target-at-maxim-group.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply